Stock ERAS ERASCA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Erasca, Inc.

Equities

ERAS

US29479A1088

Market Closed - Nasdaq
Other stock markets
 21:30:01 06/05/2024 BST 		5-day change 1st Jan Change
2.21 USD +3.27% Intraday chart for Erasca, Inc. +8.33% +3.76%
04-03 North American Morning Briefing : Powell Awaited -2- DJ
04-02 Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
AQ
North American Morning Briefing : Powell Awaited -2-
DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating
MT
Erasca Announces $45 Million Oversubscribed Private Placement Financing
GL
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
GL
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Erasca, Inc. announced that it expects to receive $45 million in funding
CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target
MT
Erasca Enters Two Supply Deals With Novartis for Trametinib
MT
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
GL
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
CI
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
AQ
North American Morning Briefing : Boeing Drags -2-
DJ
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
CI
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
GL
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ERAS Stock
  4. News Erasca, Inc.